The city of Rochester, Minnesota, currently has 11 active clinical trials seeking participants for Diabetes research studies.
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
Recruiting
The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS). Participants will be asked to: Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Type1diabetes
A Study of Non-invasive Measurement of Blood Glucose and Blood Pressure
Recruiting
The purpose of this research is to compare blood glucose, blood pressure and electrocardiogram (ECG) readings on the LIFELEAF Smartwatch compared to standard methods of measurement.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Diabetes
A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes
Recruiting
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Type 2 Diabetes Treated With Insulin
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting. A diverse population of patients with type 1 diabetes will be studied. The study population will have a large range for duration of diabetes and glycemic control, as measured by glycosylated hemoglobin (A1C). They will be enrolled in the study regardless of their prior diabetes regimen, including using Multiple Dail... Read More
Gender:
All
Ages:
Between 2 years and 80 years
Trial Updated:
01/18/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Type 1 Diabetes
A Study of Glycemic Control in Left Ventricular Assist
Recruiting
The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type 2 Diabetes Mellitus, Hyperglycemia, Hypoglycemia
The Effects of Glucagon on Hepatic Metabolism
Recruiting
Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid... Read More
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
11/01/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Obesity, Type2diabetes, NAFLD
Butyrate Adjuvant Therapy for Type 1 Diabetes
Recruiting
The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.
Gender:
All
Ages:
Between 20 years and 80 years
Trial Updated:
10/03/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type1diabetes
PDD in Type 2 Diabetes w/wo Diastolic Dysfunction
Recruiting
This study will advance the investigator's knowledge of the integrated cardiorenal and humoral physiology in type 2 diabetic patients with and without pre-clinical diastolic dysfunction, and test a novel therapeutic strategy which may prevent a progression to symptomatic Stage C heart failure
Gender:
All
Ages:
18 years and above
Trial Updated:
08/22/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Diabetes Mellitus, Type 2, Diastolic Dysfunction
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
Recruiting
This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
05/30/2023
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Healthy, Type 2 Diabetes, Obesity
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
Recruiting
Researchers are trying to understand why people with indigestion and diabetes mellitus have gastrointestinal symptoms and in particular to understand whether symptoms are related to increased sensitivity to nutrients in the small intestine. As part of this investigation, a medication called ondansetron will also be studied to determine its effects on gastrointestinal function and associated symptoms.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/26/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Indigestion, Diabetes Mellitus
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
Recruiting
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experime... Read More
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
12/27/2022
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type2diabetes